FAIR VALUE MEASUREMENTS (Tables)

12 Months Ended

Dec. 31, 2024

Fair Value Disclosures [Abstract]

Schedule of Fair Value Measurements, Recurring and Nonrecurring

Assets and liabilities measured and recorded at fair value on a recurring basis as of December 31, 2024, 2023, and 2022 consisted of the following:

		Years Ended
Dollars in thousands	Fair Value Measurement	2024		2023		2022
Assets:
Cash and cash equivalents	Level 1	$	246,375	$	276,402	$	456,661
Short-term investments	Level 1	27,192		32,694		—
Interest rate swaps	Level 2	48,795		43,556		56,712
Pension plan assets	Level 2	51,818		45,724		38,053
Foreign currency forward contracts (not designated as hedges)	Level 2	1,700		1,200		1,100
Total Assets:		$	375,880	$	399,576	$	552,526
Liabilities:
Cross currency rate swaps	Level 2	$	4,367	$	40,672	$	7,769
Net investment hedges	Level 2	31,113		49,609		5,643
Foreign currency forward contracts	Level 2	914		—		—
Contingent consideration	Level 3	69,657		87,312		74,432
Pension project benefit obligation	Level 2	67,262		65,101		50,364
Total Liabilities:		$	173,313	$	242,694	$	138,208

Schedule of Contingent Consideration

A reconciliation of the opening balances to the closing balances of these Level 3 measurements for the years ended December 31, 2024 and 2023 is as follows (in thousands):

	Contingent Consideration Liability Related to Acquisition of:
	Arkis		Location in Financial Statements	Derma Sciences		ACell		Surgical Innovations Associates, Inc.		Location in Financial Statements
Balance as of January 1, 2024	$	15,755		$	2,557	$	300	$	68,700
Payments	—			—		—		(12,400)
Change in fair value of contingent consideration liabilities	(2,787)		Research and development	129		(297)		(2,300)		Selling, general and administrative
Balance as of December 31, 2024	$	12,968		$	2,686	$	3	$	54,000
Short-Term	$	8,560		$	—	$	—	$	17,900	Accrued expenses and other current liabilities
Long-Term	4,408			2,686		3		36,100		Other liabilities
Total	$	12,968		$	2,686	$	3	$	54,000

	Contingent Consideration Liability Related to Acquisition of:
	Arkis		Location in Financial Statements	Derma Sciences		ACell Inc.		Surgical Innovations Associates, Inc.		Location in Financial Statements
Balance as of January 1, 2023	$	12,895		$	230	$	3,700	$	57,607
Additions	—			—		—		—
Change in fair value of contingent consideration liabilities	2,860		Research and development	2,327		(3,400)		11,093		Selling, general and administrative
Balance as of December 31, 2023	$	15,755		$	2,557	$	300	$	68,700
Short-Term	$	7,778		$	—	$	—	$	13,400	Accrued expenses and other current liabilities
Long-Term	7,977			2,557		300		55,300		Other liabilities
Total	$	15,755		$	2,557	$	300	$	68,700

A rollforward of the fair value of the contingent consideration liabilities, as determined by Level 3 unobservable inputs, during the years ended December 31, 2024, December 31, 2023, and December 31, 2022 were as follows:

	Years Ended
Dollars in thousands	2024		2023		2022
Balance at beginning of period	$	87,312	$	74,432	$	37,129
Change in fair value	(5,255)		12,880		37,303
Payments	(12,400)		—		—
Balance at end of period	$	69,657	$	87,312	$	74,432